Research progress on the interaction between autophagy and ferroptosis in non-alcoholic fatty liver disease

doi:10.16352/j.issn.1001-6325.2023.08.1294

Abstract

Abstract: In hepatocytes, autophagy and ferroptosis, as important biological processes in cells, play important roles in maintaining lipid accumulation homeostasis, oxidative stress and lipid peroxidation balance. Here we reviewed the impact of autophagy on the abnormal lipids accumulation in the process of liver lipid metabolism, and its relationship with ferroptosis, which was marked by oxidative stress and lipid peroxidation. The impact of the interaction between autophagy and ferroptosis on the course of non-alcoholic fatty liver disease (NAFLD) might provide some new ideas for the treatment of NAFLD.

Key words: non-alcoholic fatty liver disease, autophagy, ferroptosis, lipid metabolism

CLC Number:

LI Xiang, LI Ye. Research progress on the interaction between autophagy and ferroptosis in non-alcoholic fatty liver disease[J]. Basic & Clinical Medicine, 2023, 43(8): 1294-1298.

0
/ / Recommend

Add to citation manager EndNote|Reference Manager|ProCite|BibTeX|RefWorks

URL: http://journal11.magtechjournal.com/Jwk_jcyxylc/EN/10.16352/j.issn.1001-6325.2023.08.1294

http://journal11.magtechjournal.com/Jwk_jcyxylc/EN/Y2023/V43/I8/1294

References

[1]Zhang C, Wang J, Ding S, et al. Relationship between lifestyle and metabolic factors and carotid atherosclerosis: a survey of 47,063 fatty and non-fatty liver patients in China[J]. Front Cardiovasc Med, 2022, 9:935185. doi: 10.3389/fcvm.2022.935185.
[2]Lad A, Hunyadi J, Connolly J, et al. Antioxidant therapy significantly attenuates hepatotoxicity following low dose exposure to microcystin-LR in a murine model of diet-induced non-alcoholic fatty liver disease[J]. Antioxidants (Basel), 2022, 11:1625. doi: 10.3390/antiox11081625.
[3]Chen TQ, Deng YF, Wang YY, et al. Butyrolactone I attenuates inflammation in murine NASH by inhibiting the NF-κB signaling pathway[J]. Biochem Biophys Res Commun, 2022, 626:167-174.
[4]Jiang JJ, Zhang GF, Zheng JY, et al. Targeting mitochondrial ROS-mediated ferroptosis by quercetin alleviates high-fat diet-induced hepatic lipotoxicity[J]. Front Pharmacol, 2022, 13:876550. doi: 10.3390/antiox11081625.
[5]Bai J, Liu T, Tu B, et al. Autophagy loss impedes cancer-associated fibroblast activation via downregulating proline biosynthesis[J]. Autophagy, 2023, 19:632-643.
[6]Yan H, Zhuang M, Xu X, et al. Autophagy and its mediated mitochondrial quality control maintain pollen tube growth and male fertility in Arabidopsis[J]. Autophagy, 2023, 19:768-783.
[7]Kannangara AR, Andersen JL. Mapping the proximity interactome of ATG9A reveals unexpected dynamics of ULK1 complex proteins[J]. Autophagy, 2022, 18:2754-2755.
[8]徐玲,马红艳,杨军,等. 高脂饮食通过p-AMPK/mTOR信号通路下调小鼠肝细胞自噬水平[J].基础医学与临床,2018,38:37-41.
[9]Harada M, Hanada S, Toivola DM, et al. Autophagy activation by rapamycin eliminates mouse Mallory-Denk bodies and blocks their proteasome inhibitor-mediated formation[J]. Hepatology, 2008, 47:2026-2035.
[10]Zhou F, Ding M, Gu Y, et al. Aurantio-Obtusin attenuates non-alcoholic fatty liver disease through AMPK-mediated autophagy and fatty acid oxidation pathways[J]. Front Pharmacol, 2021, 12:826628. doi: 10.3389/fphar.2021.826628.
[11]Zhang H, Lu J, Liu H, et al. Ajugol enhances TFEB-mediated lysosome biogenesis and lipophagy to alleviate non-alcoholic fatty liver disease[J]. Pharmacol Res, 2021, 174:105964. doi: 10.1016/j.phrs.2021.105964.
[12]Luo T, Zheng Q, Shao L, et al. Intracellular delivery of glutathione peroxidase degrader induces ferroptosis in vivo[J]. Angew Chem Int Ed Engl, 2022, 4:e202206277. doi: 10.1002/anie.202206277.
[13]Song X, Liu J, Kuang F, et al. PDK4 dictates metabolic resistance to ferroptosis by suppressing pyruvate oxidation and fatty acid synthesis[J]. Cell Rep, 2021, 34:108767. doi: 10.1016/j.celrep.2021.108767.
[14]Li X, Wang TX, Huang X, et al. Targeting ferroptosis alleviates methionine-choline deficient (MCD)-diet induced NASH by suppressing liverlipotoxicity[J]. Liver Int, 2020, 40:1378-1394.
[15]Loguercio C, De Girolamo V, de Sio I, et al. Non-alcoholic fatty liver disease in an area of southern Italy: main clinical, histological, and pathophysiological aspects[J]. J Hepatol, 2001, 35:568-574.
[16]Qi J, Kim JW, Zhou Z, et al. Ferroptosis affects the progression of nonalcoholic steatohepatitis via the modulation of lipid peroxidation-mediated cell death in mice[J]. Am J Pathol, 2020, 190:68-81.
[17]Yao C, Lan D, Li X, et al. Porphyromonas gingivalis is a risk factor for the development of nonalcoholic fatty liver disease via ferroptosis[J]. Microbes Infect, 2022, 17:105040. doi: 10.1016/j.micinf.2022.105040.
[18]da Silva Lima N, Fondevila MF, Nóvoa E, et al. Inhibition of ATG3 ameliorates liver steatosis by increasing mitochondrial function[J]. J Hepatol, 2022, 76:11-24.
[19]Zhang R, Chu K, Zhao N, et al. Corilagin alleviates nonalcoholic fatty liver disease in high-fat diet-induced C57BL/6 mice by ameliorating oxidative stress and restor-ing autophagic Flux[J]. Front Pharmacol, 2019,10:1693. doi: 10.3389/fphar.2019.01693.
[20]Kang R, Zhu S, Zeh HJ, et al. BECN1 is a new driver of ferroptosis[J]. Autophagy, 2018, 14:2173-2175.
[21]Li J, Yuan J, Li Y, et al. d-Borneol enhances cisplatin sensitivity via autophagy dependent EMT signaling and NCOA4-mediated ferritinophagy[J]. Phytomedicine, 2022, 106:154411. doi: 10.1016/j.phymed.2022.154411.
[22]Gao H, Bai Y, Jia Y, et al. Ferroptosis is a lysosomal cell death process[J]. Biochem Biophys Res Commun, 2018, 503:1550-1556.
[23]Yi J, Wu S, Tan S, et al. Berberine alleviates liver fibrosis through inducing ferrous redox to activate ROS-mediated hepatic stellate cells ferroptosis[J]. Cell Death Discov, 2021, 7:374. doi: 10.1038/s41420-021-00768-7.
[24]Zhang Z, Guo M, Li Y, et al. RNA-binding protein ZFP36/TTP protects against ferroptosis by regulating autophagy signaling pathway in hepatic stellate cells[J]. Autophagy, 2020, 16:1482-1505.
[25]Pennisi G, Enea M, Romero-Gomez M, et al. Liver-related and extrahepatic events in patients with non-alcoholic fatty liver disease: a retrospective competing risks analysis[J]. Aliment Pharmacol Ther, 2022, 55:604-615.